Non-Small Cell Lung Cancer Market Size, Share & Trends Report

Non-Small Cell Lung Cancer Market Size, Share & Trends Analysis Report By Application, Regional Outlook, Competitive Strategies, And Segment Forecasts, 2019 To 2025

  • Published Date: ---
  • Base Year for Estimate: ---
  • Report ID: 674
  • Format: Electronic (PDF)
  • Historical Data: ---
  • Number of Pages: 0

The global non-small cell lung cancer market is expected to gain significant demand during the forecast period. Lung cancer is differentiated in to two types as non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Lung cancer is the uncontrolled growth of cells in the lung tissues. Majority of the lung cancer are NSCLC. Common symptoms are chest pain, wheezing, coughing up blood, hoarseness, weight loss, recurring bronchitis, loss of appetite, fatigue, shortness of breath, bone pain, swallowing difficulty and numbness of limbs. Increasing incidences of lung cancer due to smoking, air pollution (asbestos, cadmium and radon), HIV infection and population growth are few of the growth drivers of NSCLC market.

Non-small cell lung cancer market is segmented in to two types on the basis of histology and treatment. Histological segment is further subdivided in to three types as SCC or squamous cell carcinoma, large cell carcinoma and adenocarcinoma . SCC is found near bronchus in middle of the lungs in the squamous cells. Large cell carcinoma or undifferentiated type occurs in any part of the lung, fastest growing and is difficult to treat. Adenocarcinoma is slowest growing compared to other two types and is found in the cells responsible for mucous secretion in outer lungs parts. The second type treatment is further sub segmented into three types as surgery, chemotherapy and radiation. Surgery is used for first two phases of NSCLC includes pneumonectomy(entire lung removal), lobectomy (section removal of lung)and wedge resection(exclusion of part of lobe). Chemotherapy is prescribed for appreciable number of lung cancer patients. The ASCO or American Society for Clinical Oncology guidelines suggest use of platinum combination therapy for first line NSCLC treatment. Carboplatin and cisplatin are other chemotherapeutic drugs used. Radiation, the third type of treatment is used in stage one and two of NSCLC when surgical procedures are not possible. Radiation therapy is complimented with beta blockers for disease free patient survival. Diagnosis of NSCLC is a two stage process of testing and staging. Testing is done with the help of radiography, X –ray, bronchoscopy or CT biopsy. Staging is done after testing and the results are reported in tumor node metastasis or TNM system.

The geographic segmentation of non-small cell lung cancer market is into four regions such as Europe, North America, Asia Pacific and RoW. North America is expected to have largest market share followed by Europe in the forecasted period. Owing to increased smoking habits in developing countries Asia Pacific region can also be predicted to be a significant contributor to the NSCLC market. The key players in NSCLC market are Tarceva, Avastin, Gemzar, Alimta, Taxotere ,AstraZeneca,Roche and Merck KGa

Pricing & Purchase Options

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified